 |
Oncology Archives 1. Bolaños-Meade
J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik
L; Blood and Marrow Transplant Clinical Trials Network. Lymphocyte phenotype
during therapy for acute graft-versus-host disease: a brief report from
BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5. doi:
10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12. 2. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related
Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer. Cancer
Invest. 2013 Mar;31(3):183-8. doi: 10.3109/07357907.2013.767342. 3. Connolly R, Stearns V. Current approaches for
neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol. 2013 Mar
29. doi:pii: S0014-2999(13)00251-3. 10.1016/j.ejphar.2013.02.057. [Epub
ahead of print] 4. Cope L, Wu RC, Shih IeM, Wang TL. High level
of chromosomal aberration in ovarian cancer genome correlates with poor
clinical outcome. Gynecol Oncol. 2013 Mar;128(3):500-5. doi: 10.1016/j.ygyno.2012.11.031.
Epub 2012 Nov 28. 5. Durand CM, Ambinder RF. Hematopoietic stem
cell transplantation in HIV-1-infected individuals: clinical challenges
and the potential for viral eradication. Curr Opin Oncol. 2013 Mar;25(2):180-6.
doi: 10.1097/CCO.0b013e32835d814a. 6. Holdhoff M, Rosner GL, Alcorn S, Grossman SA.
'Elderly' patients with newly diagnosed glioblastoma deserve optimal
care. J Neurooncol. 2013 Mar 23. [Epub ahead of print] 7. Hossain MZ, Gilbert SF, Patel K, Ghosh S, Bhunia
AK, Kern SE. Biological clues to potent DNA-damaging activities in food
and flavoring. Food Chem Toxicol. 2013 May;55:557-67. doi: 10.1016/j.fct.2013.01.058.
Epub 2013 Feb 8. 8. Manning ML, Williams SA, Jelinek CA, Kostova
MB, Denmeade SR. Proteolysis of complement factors iC3b and C5 by the
serine protease prostate-specific antigen in prostatic fluid and seminal
plasma. J Immunol. 2013 Mar 15;190(6):2567-74. doi: 10.4049/jimmunol.1200856.
Epub 2013 Feb 11. 9. Murray-Stewart T, Woster PM, Casero RA Jr.
The re-expression of the epigenetically silenced e-cadherin gene by
a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor
in human acute myeloid leukemia cell lines. Amino Acids. 2013 Mar 19.
[Epub ahead of print] 10. Rudin CM, Brahmer JR, Juergens RA, Hann CL,
Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study
of pemetrexed and itraconazole as second-line therapy for metastatic
nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013 Mar 29.
[Epub ahead of print] 11. Rudin CM, Hong K, Streit M. Molecular characterization
of acquired resistance to the BRAF inhibitor dabrafenib in a patient
with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 2013 Mar
21. [Epub ahead of print] 12. Vogelstein B, Papadopoulos N, Velculescu VE,
Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013
Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. Review. 13. Zinn RL, Gardner EE, Dobromilskaya I, Murphy
S, Marchionni L, Hann CL, Rudin CM. Combination treatment with ABT-737
and chloroquine in preclinical models of small cell lung cancer. Mol
Cancer. 2013 Mar 2;12:16. doi: 10.1186/1476-4598-12-16. 14. Zinn RL, Gardner EE, Marchionni L, Murphy
SC, Dobromilskaya I, Hann CL, Rudin CM. ERK phosphorylation is predictive
of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer
Ther. 2013 Mar 20. [Epub ahead of print] 15. Yegnasubramanian S, Maitra A. Aiming
for the outliers: cancer precision medicine through targeting kinases
with extreme expression. Cancer Discov. 2013 Mar;3(3):252-4. doi: 10.1158/2159-8290.CD-13-0016.
1. Chang CL, Hsu YT,
Wu CC, Lai YZ, Wang C, Yang YC, Wu TC, Hung CF. Dose-dense 2. Choi SM, Kim Y, Shim JS, Park JT, Wang RH,
Leach SD, Liu JO, Deng CX, Ye Z, 3. Connolly R, Nguyen NK, Sukumar S. Molecular
Pathways: Current Role and Future 4. Heikamp EB, Powell JD. Sensing the immune microenvironment
to coordinate T 5. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL,
Davis-Sproul J, Ghosh N, Symons H, 6. Khatcheressian JL, Hurley P, Bantug E, Esserman
LJ, Grunfeld E, Halberg F, 7. Lipson EJ, Sharfman WH, Drake CG, Wollner I,
Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer
JR, Topalian SL. Durable Cancer Regression Off-Treatment and Effective
Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2013
Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov
20. PubMed PMID: 23169436; 8. Luitweiler EM, Henson BW, Pryce EN, Patel V,
Coombs G, McCaffery JM, Desai PJ. Interactions of the KSHV nuclear egress
complex: ORF69 is a potent factor for re-modeling cellular membranes.
J Virol. 2013 Jan 30. [Epub ahead of print] 9. Matthaei H, Molin MD, Maitra A. Identification
and analysis of precursors to invasive pancreatic cancer. Methods Mol
Biol. 2013;980:1-12. doi: 10.1007/978-1-62703-287-2_1. 10. Sison EA, Rau RE, McIntyre E, Li L, Small
D, Brown P. MLL-rearranged acute 11. Williams AB, Nguyen B, Li L, Brown P, Levis
M, Leahy D, Small D. Mutations of 1. Bechan GI, Lee DW,
Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT,
Kruisbeek AM, Egeler RM, Arceci RJ. Phage display generation of a novel
human anti-CD1A monoclonal antibody with potent cytolytic activity.
Br J Haematol. 2012 Nov;159(3):299-310. 2. Bolaños-Meade J, Fuchs EJ, Luznik L,
Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone
marrow transplantation with posttransplant cyclophosphamide expands
the donor pool for patients with sickle cell disease. Blood. 2012 Nov
22;120(22):4285-91. 4. Jackson CM, Flies DB, Mosse CA, Parwani A,
Hipkiss EL, Drake CG. Strain-specific induction of experimental autoimmune
prostatitis (EAP) in mice. Prostate. 2012 Nov 5. doi: 10.1002/pros.22606.
[Epub ahead of print] 5. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA,
Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ,
McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M,
Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules
of flavopiridol given as timed sequential therapy with cytosine arabinoside
and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous
leukemia. Haematologica. 2012 Nov;97(11):1736-42. 8. Lipson EJ, Sharfman WH, Drake CG, Wollner I,
Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer
JR, Topalian SL. Durable Cancer Regression Off-treatment and Effective
Re-induction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2012
Nov 20. [Epub ahead of print] 9. Luo W, Chang R, Zhong J, Pandey A, Semenza
GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible
factor 1 that is required for breast cancer progression. Proc Natl Acad
Sci U S A. 2012 Dec 4;109(49):E3367-76. 10. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez
RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin
Emerg Drugs. 2012 Dec;17(4):469-92. 11. Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek
MA. Quantitation of unbound sunitinib and its metabolite N-desethyl
sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid
chromatography-tandem mass spectrometry: application to a pharmacokinetic
study. Biomed Chromatogr. 2012 Nov;26(11):1315-24. 12. Ren YR, Chaerkady R, Hu S, Wan J, Qian J,
Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control
locus driving expression of the cancer-specific therapeutic and diagnostic
target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10. 13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke
C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith
BD, Levis M. Terminal myeloid differentiation in vivo is induced by
FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Nov 15;120(20):4205-14.
14. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines
for pancreatic cancer. Cancer J. 2012 Nov;18(6):642-52. 1. Dluzniewski PJ,
Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M,
Fallin MD, Xu J, Isaacs WB, Platz EA. Variation in IL10 and other genes
involved in the immune response and in oxidation and prostate cancer
recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1774-82.
doi: 10.1158/1055-9965.EPI-12-0458. Epub 2012 Aug 2. 2. Huo JS, Zambidis ET. Pivots of pluripotency:
The roles of non-coding RNA in regulating embryonic and induced pluripotent
stem cells. Biochim Biophys Acta. 2012 Oct 24. doi:pii: S0304-4165(12)00300-5.
10.1016/j.bbagen.2012.10.014. [Epub ahead of print] 3. Isaacs JT, D'Antonio JM, Chen S, Antony L,
Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation
of androgen receptor provides a paradigm shifting rationale for bipolar
androgen therapy (BAT) for castrate resistant human prostate cancer.
Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub
2012 Mar 6. 4. Karp JE, Thomas BM, Greer JM, Sorge C, Gore
SD, Pratz KW, Smith BD, Flatten K, Peterson KL, Schneider P, Mackey
K, Freshwater T, Levis M, McDevitt M, Carraway HE, Gladstone DE, Showel
MM, Loechner S, Parry DA, Horowitz JA, Issacs R, Kaufmann SH. Phase
I and pharmacologic trial of cytosine arabinoside with the selective
checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin
Cancer Res. 2012 Nov 12. [Epub ahead of print] 5. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh
PC, Loeb S. The impact of anatomical radical retropubic prostatectomy
on cancer control: the 30-year anniversary. J Urol. 2012 Oct 18. doi:pii:
S0022-5347(12)04485-0. 10.1016/j.juro.2012.08.028. [Epub ahead of print]
6. Raabe EH, Eberhart CG. Methylome alterations
"mark" new therapeutic opportunities in glioblastoma. Cancer
Cell. 2012 Oct 16;22(4):417-8. doi: 10.1016/j.ccr.2012.10.001. 7. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu
H, Pandey A, Kern SE. Unbiased discovery of interactions at a control
locus driving expression of the cancer-specific therapeutic and diagnostic
target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10. doi:
10.1021/pr300797v. Epub 2012 Oct 12. 8. Rudin CM, Durinck S, Stawiski EW, Poirier JT,
Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers
CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri
S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H,
Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia
M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri
S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified
gene in small-cell lung cancer. Nat Genet. 2012 Oct;44(10):1111-6. doi:
10.1038/ng.2405. Epub 2012 Sep 2. 9. Terezakis SA, Kasamon YL. Tailored strategies
for radiation therapy in classical Hodgkin's lymphoma. Crit Rev Oncol
Hematol. 2012 Oct;84(1):71-84. doi: 10.1016/j.critrevonc.2012.02.006.
1. Armanios M, Blackburn
EH. The telomere syndromes. Nat Rev Genet. 2012 Oct;13(10):693-704.
doi: 10.1038/nrg3246. Epub 2012 Sep 11. 2. Boikos SA, Hammers HJ. Denosumab for the treatment
of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012 Sep 4.
[Epub ahead of print] 3. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade
SR. Targeting carcinoma-associated fibroblasts within the tumor stroma
with a fibroblast activation protein-activated prodrug. J Natl Cancer
Inst. 2012 Sep 5;104(17):1320-34. Epub 2012 Aug 21. 4. Chen S, Principessa L, Isaacs JT. Human prostate
cancer initiating cells isolated directly from localized cancer do not
form prostaspheres in primary culture. Prostate. 2012 Sep 15;72(13):1478-89.
doi: 10.1002/pros.22503. Epub 2012 Mar 6. 5. Chu SH, Heiser D, Li L, Kaplan I, Collector
M, Huso D, Sharkis SJ, Civin C, Small D. FLT3-ITD Knockin Impairs Hematopoietic
Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm.
Cell Stem Cell. 2012 Sep 7;11(3):346-58. 6. D'Souza G, Burk RD, Zhong Y, Minkoff H, Massad
LS, Xue X, Watts DH, Anastos K, Palefsky JM, Levine AM, Colie C, Castle
PE, Strickler HD. Cervicovaginal human papillomavirus (HPV)-infection
before and after hysterectomy: evidence of different tissue tropism
for oncogenic and nononcogenic HPV types in a cohort of HIV-positive
and HIV-negative women. Int J Cancer. 2012 Sep 15;131(6):1472-8. doi:
10.1002/ijc.27363. Epub 2012 Jan 3. 7. Fuchs EJ. Human leukocyte antigen-haploidentical
stem cell transplantation using T-cell-replete bone marrow grafts. Curr
Opin Hematol. 2012 Sep 5. [Epub ahead of print] 8. Jones RJ. Haploidentical transplantation -
repurposing cyclophosphamide. Biol Blood Marrow Transplant. 2012 Sep
27. pii: S1083-8791(12)00370-9. doi: 10.1016/j.bbmt.2012.09.005. [Epub
ahead of print] 9. McMillan R, Matsui W. Molecular pathways: the
hedgehog signaling pathway in cancer. Clin Cancer Res. 2012 Sep 15;18(18):4883-8.
Epub 2012 Jun 19. 10. Poirier JT, Reddy PS, Idamakanti N, Li SS,
Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM. Characterization of
a full-length infectious cDNA clone and a green fluorescent protein
reporter derivative of the oncolytic picornavirus SVV-001. J Gen Virol.
2012 Sep 12. [Epub ahead of print] 11. Rudin CM, Durinck S, Stawiski EW, Poirier
JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J,
Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman
R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z,
Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei
PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD,
Brock MV, Seshagiri S. Comprehensive genomic analysis identifies SOX2
as a frequently amplified gene in small-cell lung cancer. Nat Genet.
2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2. 12. Santa-Maria CA, Cimino-Mathews A, Moseley
KF, Wolff AC, Blakeley JO, Connolly RM. Complete Radiologic Response
and Long-Term Survival With Use of Systemic High-Dose Methotrexate for
Breast Cancer-Associated Leptomeningeal Disease. Clin Breast Cancer.
2012 Sep 22. pii: S1526-8209(12)00174-7. doi: 10.1016/j.clbc.2012.07.010.
[Epub ahead of print] 13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke
C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith
BD, Levis M. Terminal myeloid differentiation in vivo is induced by
FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Sep 25. [Epub ahead of
print] 14. Suarez L, Gore SD. Cp-jeez! Aza-natomy! Blood.
2012 Sep 20;120(12):2354-5. 15. Waickman AT, Powell JD. mTOR, metabolism,
and the regulation of T-cell differentiation and function. Immunol Rev.
2012 Sep;249(1):43-58. doi: 10.1111/j.1600-065X.2012.01152.x. 1. Abd Elmoneim A,
Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott
T, Arceci RJ. Phase I dose-escalation trial of clofarabine followed
by escalating doses of fractionated cyclophosphamide in children with
relapsed or refractory acute leukemias. Pediatr Blood Cancer. 2012 Aug
8. doi: 10.1002/pbc.24264. [Epub ahead of print] 2. Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian
R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Maarten Egeler
R, Arceci RJ. Phage display generation of a novel human anti-CD1A monoclonal
antibody with potent cytolytic activity. Br J Haematol. 2012 Aug 30.
doi: 10.1111/bjh.12033. [Epub ahead of print] 3. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade
SR. Targeting carcinoma-associated fibroblasts within the tumor stroma
with a fibroblast activation protein-activated prodrug. J Natl Cancer
Inst. 2012 Sep 5;104(17):1320-34. Epub 2012 Aug 21. 4. Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee
SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. PSMA-targeted
theranostic nanoplex for prostate cancer therapy. ACS Nano. 2012 Sep
25;6(9):7752-62. 5. Cidado J, Park BH. Targeting the PI3K/Akt/mTOR
pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2012
Aug 4. [Epub ahead of print] 6. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo
AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Issacs WB,
Platz EA. Variation in IL10 and other genes involved in the immune response
and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers
Prev. 2012 Sept 25. [Epub ahead of print] 7. Holdhoff M, Ye X, Blakeley JO, Blair L, Burger
PC, Grossman SA, Diaz LA Jr. Use of personalized molecular biomarkers
in the clinical care of adults with glioblastomas. J Neurooncol. 2012
Aug 29. [Epub ahead of print] 8. Kreitler D, Capuano CM, Henson BW, Pryce EN,
Anacker D, McCaffery JM, Desai PJ. The assembly domain of the small
capsid protein of Kaposi's sarcoma-associated herpesvirus. J Virol.
2012 Aug 22. [Epub ahead of print] 9. Penchev VR, Rasheed ZA, Maitra A, Matsui W.
Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer
Res. 2012 Aug 15;18(16):4277-84. 10. Williams AB, Li L, Nguyen B, Brown P, Levis
M, Small D. Fluvastatin inhibits FLT3 glycosylation in human and murine
cells and prolongs survival of mice with FLT3/ITD leukemia. Blood. 2012
Aug 27. [Epub ahead of print] 11. Zeidan A, Bolanños-Meade J, Kasamon
Y, Aoki J, Borowitz M, Swinnen L, Symons H, Luznik L, Fuchs E, Jones
R, Ambinder R. Human leukocyte antigen-haploidentical hematopoietic
stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma.
2012 Aug 27. [Epub ahead of print] 1. Bhan S, Chuang A,
Negi SS, Glazer CA, Califano JA. MAGEA4 induces growth in normal oral
keratinocytes by inhibiting growth arrest and apoptosis. Oncol Rep.
2012 Jul 25. doi: 10.3892/or.2012.1934. [Epub ahead of print] 2. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida
T, Hong SM, de Wilde RF, Zhang Z, Huso D, Zhao M, Rudek M, Stearns V,
Maitra A, Sukumar S. Intraductal administration of a polymeric nanoparticle
formulation of curcumin (NanoCurc) significantly attenuates incidence
of mammary tumors in a rodent chemical carcinogenesis model implications
for breast cancer chemoprevention in at-risk populations. Carcinogenesis.
2012 Jul 25. [Epub ahead of print] 3. Denmeade SR, Isaacs JT. Engineering enzymatically
activated "Molecular Grenades" for cancer. Oncotarget. 2012
Jul 22. [Epub ahead of print] 4. Manning ML, Kostova M, Williams SA, Denmeade
SR. Trypsin-like proteolytic contamination of commercially available
psa purified from human seminal fluid. Prostate. 2012 Aug 1;72(11):1233-8.
doi: 10.1002/pros.22474. Epub 2011 Dec 28. 5. Schweizer MT, Antonarakis ES. Abiraterone and
other novel androgen-directed strategies for the treatment of prostate
cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012
Aug;4(4):167-78. 6. Pellakuru LG, Iwata T, Gurel B, Schultz D,
Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM. Global levels of
H3K27me3 Track with differentiation in vivo and are deregulated by MYC
in prostate cancer. Am J Pathol. 2012 Aug;181(2):560-9. 7. Wenzel J, Jones RA, Klimmek R, Krumm S, Darrell
LP, Song D, Stearns V, Ford JG. Cancer support and resource needs among
african american older adults. Clin J Oncol Nurs. 2012 Aug 1;16(4):372-7.
8. Williams AB, Nguyen B, Li L, Brown P, Levis
M, Leahy D, Small D. Mutations of FLT3/ITD confer resistance to multiple
tyrosine kinase inhibitors. Leukemia. 2012 Jul 13. doi: 10.1038/leu.2012.191.
[Epub ahead of print] 1. Chun YS, Yoshida
T, Mori T, Huso DL, Zhang Z, Stearns V, Perkins B, Jones RJ, Sukumar
S. Intraductally administered pegylated liposomal doxorubicin reduces
mammary stem cell function in the mammary gland but in the long term,
induces malignant tumors. Breast Cancer Res Treat. 2012 Jul 1. [Epub
ahead of print] 2. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN,
Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci
MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.
Engineering a prostate-specific membrane antigen-activated tumor endothelial
cell prodrug for cancer therapy. Sci Transl Med. 2012 Jun 27;4(140):140ra86.
3. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht
JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner
KS, Vogelstein B. The molecular evolution of acquired resistance to
targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40.
4. Le DT, Jaffee EM. Regulatory T-cell modulation
using cyclophosphamide in vaccine approaches: a current perspective.
Cancer Res. 2012 Jul 3. [Epub ahead of print] 5. McMillan R, Matsui W. Molecular Pathways: The
hedgehog signaling pathway in cancer. Clin Cancer Res. 2012 Jun 19.
[Epub ahead of print] 6. Nwankwo N, Zhang Z, Wang T, Collins C, Resta
L, Ermisch S, Day J, Decker R, Kornberg L, Nicol S, Thornton D, Armstrong
DK, Carducci MA. Phase I study of enzastaurin and bevacizumab in patients
with advanced cancer: safety, efficacy and pharmacokinetics. Invest
New Drugs. 2012 Jul 6. [Epub ahead of print] 7. Pan F, Barbi J, Pardoll DM. Hypoxia-inducible
factor 1: A link between metabolism and T cell differentiation and a
potential therapeutic target. Oncoimmunology. 2012 Jul 1;1(4):510-515.
8. Rudin CM. Vismodegib. Clin Cancer Res. 2012
Jun 15;18(12):3218-22. Epub 2012 Jun 7. 9. Smith BD. Myelodysplastic syndromes: challenges
to improving patient and caregiver satisfaction. Am J Med. 2012 Jul;125(7
Suppl):S26-30. 10. Zeidan AM, Ricklis RM, Carraway HE,
Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel
MM, Gladstone DE, Gore SD, Karp JE. Phase 1 dose-escalation trial of
clofarabine followed by escalating dose of fractionated cyclophosphamide
in adults with relapsed or refractory acute leukaemias. Br J Haematol.
2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub
2012 May 18. 1. Antonarakis ES,
Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci
MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising
PTEN, MYC, and Ki67 predicts progression in prostate cancer patients
receiving adjuvant docetaxel after prostatectomy. Cancer. 2012 Jun 6.
doi: 10.1002/cncr.27689. [Epub ahead of print] 2. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru
DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz
LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic
and pharmacodynamic study of cetuximab, irinotecan and sorafenib in
advanced colorectal cancer. Invest New Drugs. 2012 May 22. [Epub ahead
of print] 3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian
SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O,
Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso
JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta
A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients
with advanced cancer. N Engl J Med. 2012 Jun 2. [Epub ahead of print] 4. Forde PM, Rudin CM. Crizotinib in the treatment
of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201.
5. Greenblatt S, Small D. FLT3 in lineage specification
and plasticity. Oncotarget. 2012 May 27. [Epub ahead of print] 6. Jelovac D, Armstrong DK. Role of Farletuzumab
in Epithelial Ovarian Carcinoma. Curr Pharm Des. 2012 May 14. [Epub
ahead of print] 7. Higgins MJ, Jelovac D, Barnathan E, Blair B,
Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L,
Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P,
Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH. Detection of tumor
PIK3CA status in metastatic breast cancer using peripheral blood. Clin
Cancer Res. 2012 Jun 4. [Epub ahead of print] 8. Jelovac D, Wolff AC. The adjuvant treatment
of HER2-positive breast cancer. Curr Treat Options Oncol. 2012 Jun;13(2):230-9.
9. Keenan BP, Jaffee EM. Whole cell vaccines-past
progress and future strategies. Semin Oncol. 2012 Jun;39(3):276-86.
10. Khaliq W, Meyer CF, Uzoaru I, Wolf RM, Antonarakis
ES. Prostate angiosarcoma: is there any association with previous radiation
therapy? BJU Int. 2012 May 15. doi: 10.1111/j.1464-410X.2012.11202.x.
[Epub ahead of print] 11. Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical
Development of Listeria monocytogenes-Based Immunotherapies. Semin Oncol.
2012 Jun;39(3):311-22. 12. Lodge MA, Chaudhry MA, Wahl RL. Noise considerations
for PET quantification using maximum and peak standardized uptake value.
J Nucl Med. 2012 May 24. [Epub ahead of print] 13. Waickman AT, Alme A, Senaldi L, Zarek PE,
Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion
of the A(2A) adenosine receptor. Cancer Immunol Immunother. 2012 Jun;61(6):917-26.
Epub 2011 Nov 25. 14. Waickman AT, Powell JD. Mammalian target
of rapamycin integrates diverse inputs to guide the outcome of antigen
recognition in T cells. J Immunol. 2012 May 15;188(10):4721-9. 15. Vogelstein B, Roberts NJ, Vogelstein
JT, Parmigiani G, Kinzler KW, Velculescu VE. Response to comments on
"the predictive capacity of personal genome sequencing". Sci
Transl Med. 2012 May 23;4(135):135lr3. 1. Antonarakis ES,
Drake CG. Combining immunological and androgen-directed approaches:
an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol.
2012 May;24(3):258-65. 2. Armanios M. An emerging role for the conserved
telomere component 1 (CTC1) in human genetic disease. Pediatr Blood
Cancer. 2012 May 3. doi: 10.1002/pbc.24200. [Epub ahead of print] 3. Baylin SB. The cancer epigenome: its origins,
contributions to tumorigenesis, and translational implications. Proc
Am Thorac Soc. 2012 May;9(2):64-5. 4. Dalrymple SL, Becker RE, Zhou H, DeWeese TL,
Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated
radiation resulting in an enhanced therapeutic response of prostate
cancer xenografts. Prostate. 2012 May 1;72(6):638-48. doi: 10.1002/pros.21467.
Epub 2011 Aug 11. 5. Drake CG, Antonarakis ES. Current status of
immunological approaches for the treatment of prostate cancer. Curr
Opin Urol. 2012 May;22(3):197-202. 6. Easwaran H, Johnstone SE, Van Neste L, Ohm
J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D,
Collisson E, Zhu J, Yegnasubramanian S, Matsui W, Baylin SB. A DNA hypermethylation
module for the stem/progenitor cell signature of cancer. Genome Res.
2012 May;22(5):837-49. Epub 2012 Mar 5. 7. Easwaran H, Baylin SB. Biomarkers for EGFR-Antagonist
Response: In the Genes and on the Genes! Clin Cancer Res. 2012 Apr 15;18(8):2121-3.
Epub 2012 Feb 27. 8. Emens LA, Silverstein SC, Khleif S, Marincola
FM, Galon J. Toward integrative cancer immunotherapy: targeting the
tumor microenvironment. J Transl Med. 2012 Apr 10;10:70. 9. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ,
Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman
JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD
in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. Epub
2012 Feb 16. 10. Laheru D, Shah P, Rajeshkumar NV, McAllister
F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao
M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical
development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib)
in pancreatic cancer. Invest New Drugs. 2012 May 1. [Epub ahead of print]
11. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler
KW, Vogelstein B, Velculescu VE. The predictive capacity of personal
genome sequencing. Sci Transl Med. 2012 Apr 25. [Epub ahead of print]
12. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira
M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS,
Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A,
Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse
RA, Shapiro GI, Gandhi L. Phase 2 study of single agent navitoclax (ABT
263) and biomarker correlates in patients with relapsed small cell lung
cancer. Clin Cancer Res. 2012 Apr 11. [Epub ahead of print] 13. Sanguineti G, Sormani MP, Marur S, Gunn GB,
Rao N, Cianchetti M, Ricchetti F, McNutt T, Wu B, Forastiere A. Effect
of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated
radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol
Phys. 2012 May 1;83(1):235-42. Epub 2011 Nov 19. 1. Antonarakis ES,
Carducci MA. Targeting angiogenesis for the treatment of prostate cancer.
Expert Opin Ther Targets. 2012 Apr;16(4):365-76. Epub 2012 Mar 13. 2. Emens LA. Re-purposing cancer therapeutics
for breast cancer immunotherapy. Cancer Immunol Immunother. 2012 Mar
28. [Epub ahead of print]
3. Gladstone DE, Blackford
A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade
J, Jones RJ. The importance of IGHV mutational status in del(11q) and
del(17p) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012
Apr;12(2):132-7. Epub 2012 Jan 28. 4. Grossman SA, Ye X, Peereboom D, Rosenfeld MR,
Mikkelsen T, Supko JG, Desideri S; for the Adult Brain Tumor Consortium,
Baltimore, MD. Phase I study of terameprocol in patients with recurrent
high-grade glioma. Neuro Oncol. 2012 Apr;14(4):511-517. Epub 2012 Feb
8. 5. Greenblatt S, Li L, Slape C, Nguyen B, Novak
R, Duffield A, Huso D, Desiderio S, Borowitz MJ, Aplan P, Small D. Knock-in
of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate
acute myeloid leukemia in a mouse model. Blood. 2012 Mar 22;119(12):2883-94.
Epub 2012 Feb 8. 6. Guo H, Ma O, Speck NA, Friedman AD. Runx1 deletion
or dominant inhibition reduces Cebpa transcription via conserved promoter
and distal enhancer sites to favor monopoiesis over granulopoiesis.
Blood. 2012 Mar 26. [Epub ahead of print]
7. Paller CJ, Antonarakis
E. Sipuleucel-T for the treatment of metastatic prostate cancer: Promise
and challenges. Hum Vaccin Immunother. 2012 Apr 1;8(4). [Epub ahead
of print]
8. Pardoll DM. The
blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer.
2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. 9. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler
KW, Vogelstein B, Velculescu VE. The predictive capacity of personal
genome sequencing. Sci Transl Med. 2012 Apr 2. [Epub ahead of print]
10. Shamay M, Hand
N, Lemas MV, Koon HB, Krown SE, Wrangle J, Desai P, Ramos JC, Ambinder
RF. CpG methylation as a tool to characterize cell-free kaposi sarcoma
herpesvirus DNA. J Infect Dis. 2012 Apr;205(7):1095-9. Epub 2012 Feb
22. 11. Topalian SL, Drake CG, Pardoll DM. Targeting
the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr
Opin Immunol. 2012 Apr;24(2):207-12. Epub 2012 Jan 9. 12. Tsai HC, Li H, Van Neste L, Cai Y, Robert
C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen
RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC,
Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB,
Zahnow CA. Transient low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells. Cancer
Cell. 2012 Mar 20;21(3):430-46. 13. Vogelstein B, Kinzler KW. Winning the war:
science parkour. Sci Transl Med. 2012 Mar 28;4(127):127ed2. 14. Weiss VL, Lee TH, Song H, Kouo TS, Black CM,
Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific
T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like
regulatory T cells. PLoS One. 2012;7(2):e31962. 15. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak
M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis
ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in
men with biochemically recurrent prostate cancer. Prostate. 2012 Apr;72(5):487-98.
doi: 10.1002/pros.21449. 1. Drake CG, Antonarakis
ES. Current status of immunological approaches for the treatment of
prostate cancer. Curr Opin Urol. 2012 Feb 9. [Epub ahead of print] 2. Chen S, Principessa
L, Isaacs JT. Human prostate cancer initiating cells isolated directly
from localized cancer do not form prostaspheres in primary culture.
Prostate. 2012 Mar 6. doi: 10.1002/pros.22503. [Epub ahead of print]
3. Easwaran H, Baylin SB. Biomarkers for EGFR-antagonist
response: In the genes, and on the genes! Clin Cancer Res. 2012 Feb
27. [Epub ahead of print] 4. Easwaran H, Johnstone S, Vanneste L, Ohm J,
Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson
E, Zhu JC, Yegnasubramanian S, Matsui W, Baylin SB. A DNA hypermethylation
module for the stem/progenitor cell signature of cancer. Genome Res.
2012 Mar 5. [Epub ahead of print] 5. Ghiaur G, Gerber JM, Matsui W, Jones RJ. Cancer
stem cells: relevance to clinical transplantation. Curr Opin Oncol.
2012 Mar;24(2):170-5. 6. Gladstone DE, Fuchs E. Hematopoietic stem cell
transplantation for chronic lymphocytic leukemia. Curr Opin Oncol. 2012
Mar;24(2):176-81. 7. Isaacs JT, D'Antonio JM, Chen S, Antony L,
Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation
of androgen receptor provides a paradigm shifting rationale for bipolar
androgen therapy (BAT) for castrate resistant human prostate cancer.
Prostate. 2012 Mar 6. doi: 10.1002/pros.22504. [Epub ahead of print]
8. Jin K, Kong X, Shah T, Penet MF, Wildes F,
Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X,
Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S. The HOXB7 protein
renders breast cancer cells resistant to tamoxifen through activation
of the EGFR pathway. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2736-41.
Epub 2011 Jun 20. 9. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ,
Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman
JM, Matsui WH, Jones RJ, Ambinder RF. A phase II study of rituximab-ABVD
in classical Hodgkin lymphoma. Blood. 2012 Feb 16. [Epub ahead of print]
10. Mullins JK, Loeb S. Environmental exposures
and prostate cancer. Urol Oncol. 2012 Mar;30(2):216-9. 11. Pardoll D, Drake C. Immunotherapy earns its
spot in the ranks of cancer therapy. J Exp Med. 2012 Feb 13;209(2):201-9.
PubMed PMID: 22330682; 12. Rasheed ZA, Matsui W. Biological and clinical
relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol
Hepatol. 2012 Mar;27 Suppl 2:15-8. doi: 10.1111/j.1440-1746.2011.07015.x.
13. Shamay M, Hand N, Lemas MV, Koon HB, Krown
SE, Wrangle J, Desai P, Ramos JC, Ambinder RF. CpG methylation as a
tool to characterize cell-free kaposi sarcoma herpesvirus DNA. J Infect
Dis. 2012 Apr;205(7):1095-9. Epub 2012 Feb 22. 1. Armanios M, Price
C. Telomeres and disease: An overview. Mutat Res. 2012 Feb 1;730(1-2):1-2.
2. Armanios M. Telomerase and idiopathic pulmonary
fibrosis. Mutat Res. 2012 Feb 1;730(1-2):52-8. 3. Bardia A, Arieas ET, Zhang Z, Defilippis A,
Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden
J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff
AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer
recurrence risk and cardiovascular disease incidence risk among postmenopausal
women with breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):907-14.
4. Clements EG, Mohammad HP, Leadem BR, Easwaran
H, Cai Y, Van Neste L, Baylin SB. DNMT1 modulates gene expression without
its catalytic activity partially through its interactions with histone-modifying
enzymes. Nucleic Acids Res. 2012 Jan 25. [Epub ahead of print] 5. De Jesus-Acosta A, Oliver GR, Blackford A,
Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D,
Laheru D, Le DT, Chung K, Diaz LA Jr. A multicenter analysis of GTX
chemotherapy in patients with locally advanced and metastatic pancreatic
adenocarcinoma. Cancer Chemother Pharmacol. 2012 Feb;69(2):415-24. 6. Fraser AV, Goodwin AC, Hacker-Prietz A, Sugar
E, Woster PM, Casero RA Jr. Knockdown of ornithine decarboxylase antizyme
1 causes loss of uptake regulation leading to increased N (1), N (11)-bis(ethyl)norspermine
(BENSpm) accumulation and toxicity in NCI H157 lung cancer cells. Amino
Acids. 2012 Feb;42(2-3):529-38. 7. Gladstone DE, Blackford A, Cho E, Swinnen L,
Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ. The
Importance of IGHV mutational status in del(11q) and del(17p) chronic
lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Jan 27. [Epub
ahead of print] 8. Hooker CM, Meguid RA, Hulbert A, Taylor JT,
Shin J, Wrangle J, Rodgers K, Lee B, Laskshmanan S, Brown T, Meneshian
A, Sussman M, Keruly J, Moore RD, Yang SC, Brock MV. Human immunodeficiency
virus infection as a prognostic factor in surgical patients with non-small
cell lung cancer. Ann Thorac Surg. 2012 Feb;93(2):405-12. 9. Higgins MJ, Prowell TM, Blackford AL, Byrne
C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens
LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd
E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. A short-term biomarker
modulation study of simvastatin in women at increased risk of a new
breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):915-24. Epub
2011 Nov 11. 10. Le DT, Brockstedt DG, Nir-Paz R, Hampl J,
Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin
M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P,
Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated listeria
vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing
mesothelin (CRS-207) for advanced cancers: phase i studies of safety
and immune induction. Clin Cancer Res. 2012 Feb 1;18(3):858-868. Epub
2011 Dec 6. 11. Levis M. Phospho-specific Flow: Fixating on
the target. Clin Cancer Res. 2012 Feb 2. [Epub ahead of print] 12. Noonan K, Rudraraju L, Ferguson A, Emerling
A, Pasetti M, Huff CA, Borrello I. Lenalidomide-induced immunomodulation
in multiple myeloma: impact on vaccines and antitumor responses. Clin
Cancer Res. 2012 Feb 2. [Epub ahead of print] 13. Shabbeer S, Williams SA, Simons BW, Herman
JG, Carducci MA. Progression of prostate carcinogenesis and dietary
methyl donors: temporal dependence. Cancer Prev Res (Phila). 2012 Feb;5(2):229-39.
Epub 2011 Dec 2. 14. Zhu Q, Huang Y, Marton LJ, Woster PM,
Davidson NE, Casero RA Jr. Polyamine analogs modulate gene expression
by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin
structure in human breast cancer cells. Amino Acids. 2012 Feb;42(2-3):887-98.
Epub 2011 Jul 30. 1. Antonarakis ES, Carducci MA, Eisenberger MA,
Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris
MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA
(prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant
prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2011 Oct
22. [Epub ahead of print] 2. Armstrong DK, Visvanathan K. The "luxury"
of second malignancies. Gynecol Oncol. 2011 Dec;123(3):453-4. Epub 2011
Oct 11. 3. Chen Y, Pullambhatla M, Byun Y, Foss CA, Nimmagadda
S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen
tanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate
Cancer. Clin Cancer Res. 2011 Oct 31. [Epub ahead of print] 4. Gladstone DE, Swinnen L, Kasamon Y, Blackford
A, Gocke CD, Griffin CA, Meade JB, Jones RJ. Importance of immunoglobulin
heavy chain variable region mutational status in del(13q) chronic lymphocytic
leukemia. Leuk Lymphoma. 2011 Oct;52(10):1873-81. Epub 2011 Aug 18.
5. Hong S, Skaist AM, Wheelan SJ, Friedman AD.
AP-1 protein induction during monopoiesis favors C/EBP: AP-1 heterodimers
over C/EBP homodimerization and stimulates FosB transcription. J Leukoc
Biol. 2011 Oct;90(4):643-51. Epub 2011 May 4. 6. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor
in thyroid cancer. Clin Cancer Res. 2011 Oct 15;17(20):6482-9. Epub
2011 Aug 10. 7. Jones1 S, Li M, Parsons DW, Zhang X, Wesseling
J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman
JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein
B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the
chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat.
2011 Oct 18. doi: 10.1002/humu.21633. [Epub ahead of print] 8. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith
BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE,
Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho
C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garrett-Mayer E. Multi-institutional
Phase II clinical and pharmacogenomics trial of tipifarnib plus etoposide
for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood. 2011 Oct 14. [Epub ahead of print] 9. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann
S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir
AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D,
Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa
Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park
BH. Mutation of a single allele of the cancer susceptibility gene BRCA1
leads to genomic instability in human breast epithelial cells. Proc
Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. Epub 2011 Oct 10.
10. Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR,
Hu S, Woodard C, Lin J, Taverna SD, Desai P, Ambinder RF, Hayward GS,
Qian J, Zhu H, Hayward SD. Conserved herpesvirus kinases target the
DNA damage response pathway and TIP60 histone acetyltransferase to promote
virus replication. Cell Host Microbe. 2011 Oct 4;10(4):390-400. 11. Osanyingbemi-Obidi J, Dobromilskaya I, Illei
PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic
capacity in vitro but may be circumvented in tumorigenesis in vivo.
Mol Cancer Res. 2011 Oct 12. [Epub ahead of print] 12. Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski
E, Sidransky D. Tumor protein p63/nuclear factor kappa-B feedback loop
in regulation of cell death. J Biol Chem. 2011 Oct 20. [Epub ahead of
print] 13. Topalian SL, Weiner GJ, Pardoll DM.
Cancer Immunotherapy Comes of Age. J Clin 1. Antonarakis ES,
Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell
K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study
of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal
antibody, in patients with castration-resistant prostate cancer: a PCCTC
trial. Cancer Chemother Pharmacol. 2011 Oct 22. [Epub ahead of print]
2. Armstrong DK, Visvanathan K. The "luxury"
of second malignancies. Gynecol Oncol. 2011 Dec;123(3):453-4. Epub 2011
Oct 11. 3. Chen Y, Pullambhatla M, Byun Y, Foss CA, Nimmagadda
S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen
tanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate
Cancer. Clin Cancer Res. 2011 Oct 31. [Epub ahead of print] 4. Gladstone DE, Swinnen L, Kasamon Y, Blackford
A, Gocke CD, Griffin CA, Meade JB, Jones RJ. Importance of immunoglobulin
heavy chain variable region mutational status in del(13q) chronic lymphocytic
leukemia. Leuk Lymphoma. 2011 Oct;52(10):1873-81. Epub 2011 Aug 18.
5. Hong S, Skaist AM, Wheelan SJ, Friedman AD.
AP-1 protein induction during monopoiesis favors C/EBP: AP-1 heterodimers
over C/EBP homodimerization and stimulates FosB transcription. J Leukoc
Biol. 2011 Oct;90(4):643-51. Epub 2011 May 4. 6. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor
in thyroid cancer. Clin Cancer Res. 2011 Oct 15;17(20):6482-9. Epub
2011 Aug 10. 7. Jones1 S, Li M, Parsons DW, Zhang X, Wesseling
J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman
JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein
B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the
chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat.
2011 Oct 18. doi: 10.1002/humu.21633. [Epub ahead of print] 8. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith
BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE,
Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho
C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garrett-Mayer E. Multi-institutional
Phase II clinical and pharmacogenomics trial of tipifarnib plus etoposide
for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood. 2011 Oct 14. [Epub ahead of print] 9. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann
S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir
AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D,
Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa
Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park
BH. Mutation of a single allele of the cancer susceptibility gene BRCA1
leads to genomic instability in human breast epithelial cells. Proc
Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. Epub 2011 Oct 10.
10. Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR,
Hu S, Woodard C, Lin J, Taverna SD, Desai P, Ambinder RF, Hayward GS,
Qian J, Zhu H, Hayward SD. Conserved herpesvirus kinases target the
DNA damage response pathway and TIP60 histone acetyltransferase to promote
virus replication. Cell Host Microbe. 2011 Oct 4;10(4):390-400. 11. Osanyingbemi-Obidi J, Dobromilskaya I, Illei
PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic
capacity in vitro but may be circumvented in tumorigenesis in vivo.
Mol Cancer Res. 2011 Oct 12. [Epub ahead of print] 12. Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski
E, Sidransky D. Tumor protein p63/nuclear factor kappa-B feedback loop
in regulation of cell death. J Biol Chem. 2011 Oct 20. [Epub ahead of
print] 13. Topalian SL, Weiner GJ, Pardoll DM.
Cancer Immunotherapy Comes of Age. J Clin 1. Aftab BT, Dobromilskaya
I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth
in non-small cell lung cancer. Cancer Res. 2011 Sep 6. [Epub ahead of
print] 2. Antonarakis ES, Armstrong AJ. Emerging therapeutic
approaches in the management of metastatic castration-resistant prostate
cancer. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):206-18. doi: 10.1038/pcan.2011.24.
Epub 2011 May 17. 3. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA,
Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed
with semiautomated volumetric and functional analysis of diffusion-weighted
and contrast-enhanced MR imaging data. Radiology. 2011 Sep;260(3):752-61.
Epub 2011 Jul 19. 4. Cox R, Epstein JI. Large nested variant of
urothelial carcinoma: 23 cases mimicking von brunn nests and inverted
growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg
Pathol. 2011 Sep;35(9):1337-42. 5. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan
AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma
R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo
M. Tumor engraftment in nude mice and enrichment in stroma- related
gene pathways predict poor survival and resistance to gemcitabine in
patients with pancreatic cancer. Clin Cancer Res. 2011 Sep 1;17(17):5793-800.
Epub 2011 Jul 8. 6. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber
J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG,
Netto GJ, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine
content is significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget. 2011 Sep 2. [Epub ahead of print]
7. Karafin M, Parwani AV, Netto GJ, Illei PB,
Epstein JI, Ladanyi M, Argani P. Diffuse expression of PAX2 and PAX8
in the cystic epithelium of mixed epithelial stromal tumor, angiomyolipoma
with epithelial cysts, and primary renal synovial sarcoma: evidence
supporting renal tubular differentiation. Am J Surg Pathol. 2011 Sep;35(9):1264-73.
8. Keizman D, Huang P, Eisenberger MA, Pili R,
Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors
and outcome of sunitinib treatment in patients with metastatic renal
cell carcinoma: A retrospective examination. Eur J Cancer. 2011 Sep;47(13):1955-61.
Epub 2011 May 18. 9. Lemmon CR, Woo JH, Tully E, Wilsbach K, Gabrielson
E. Nuclear factor-{kappa}B (NF-{kappa}B) mediates a protective response
in cancer cells treated with inhibitors of fatty acid synthase. J Biol
Chem. 2011 Sep 9;286(36):31457-65. Epub 2011 Jul 16. 10. Li L, Bailey E, Greenblatt S, Huso D, Small
D. Loss of the wild-type allele contributes to myeloid expansion and
disease aggressiveness in FLT3/ITD knock-in mice. Blood. 2011 Sep 8.
[Epub ahead of print] 11. Lotan T, Gurel B, Sutcliffe S, Esopi D, Liu
W, Xu J, Hicks J, Park B, Humphreys E, Partin A, Han M, Netto GJ, Isaacs
WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation
and prognostic indicator for a high risk surgical cohort of prostate
cancer patients. Clin Cancer Res. 2011 Aug 30. [Epub ahead of print]
12. Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd,
Kjær SK, Shih IeM, Roden RB. Comparison of candidate serologic
markers for type I and type II ovarian cancer. Gynecol Oncol. 2011 Sep;122(3):560-6.
13. Prowell TM, Blackford AL, Byrne C, Khouri
NF, Dowsett M, Folkerd E, Tarpinian KS, Powers P, Wright LA, Donehower
MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer
E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating
estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer
Prev Res (Phila). 2011 Sep 1. [Epub ahead of print] 14. Velculescu VE, Diaz LA Jr. Understanding the
enemy. Sci Transl Med. 2011 Aug 31;3(98):98ps37. 15. Yovino S, Grossman SA. Treatment of
glioblastoma in "elderly" patients. Curr Treat Options Oncol.
2011 Sep;12(3):253-62. 1. Alder JK, Guo N,
Kembou F, Parry EM, Anderson CJ, Gorgy AI, Walsh MF, Sussan T, Biswal
S, Mitzner W, Tuder RM, Armanios M. Telomere length is a determinant
of emphysema susceptibility. Am J Respir Crit Care Med. 2011 Jul 14.
[Epub ahead of print] 2. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak
M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO, Sidransky
D. An epigenetic marker panel for detection of lung cancer using cell-free
serum DNA. Clin Cancer Res. 2011 Jul 1;17(13):4494-4503. Epub 2011 May
24. 3. Bruno TC, Rothwell C, Grosso JF, Getnet D,
Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG. Anti-tumor effects
of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic
model. Prostate. 2011 Jul 14. doi: 10.1002/pros.21453. [Epub ahead of
print] 4. Cooper RS. Case study of a chaplain's spiritual
care for a patient with advanced 5. Humphrey RW, Brockway-Lunardi LM, Bonk DT,
Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM.
Opportunities and challenges in the development of experimental drug
combinations for cancer. J Natl Cancer Inst. 2011 Jul 15. [Epub ahead
of print] 6. Grossman SA, Ye X, Lesser G, Sloan AE, Carraway
HE, Desideri S, Piantadosi S. Immunosuppression in patients with high
grade gliomas treated with radiation and temozolomide. Clin Cancer Res.
2011 Jul 7. [Epub ahead of print] 7. Zhang L, Friedman AD. SHP2 tyrosine phosphatase
stimulates CEBPA gene expression to mediate cytokine-dependent granulopoiesis.
Blood. 2011 Jul 1. [Epub ahead of print] 1. Epstein JI. Editorial
comment. Urology. 2011 Jun;77(6):1414-5. 2. Pramanik D, Campbell NR, Karikari C, Chivukula
R, Kent OA, Mendell JT, Maitra A. Restitution of tumor suppressor microRNAs
using a systemic nanovector inhibits pancreatic cancer growth in mice.
Mol Cancer Ther. 2011 May 27. [Epub ahead of print] 3. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG,
Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart
CG. BRAF activation induces transformation and then senescence in human
neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res. 2011
Jun 1;17(11):3590-9. 4. Rasheed ZA, Kowalski J, Smith BD, Matsui W.
Concise review: emerging concepts 5. Sangster-Guity N, Conrad BH, Papadopoulos N,
Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific
manner. Oncogene. 2011 Jun 2;30(22):2526-33. 6. Shirley CM, Chen J, Shamay M, Li H, Zahnow
CA, Hayward SD, Ambinder RF. Bortezomib induction of C/EBP{beta} mediates
Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood. 2011
Jun 9;117(23):6297-303. 7. Sison EA, Brown P. The bone marrow microenvironment
and leukemia: biology and 8. Ueland FR, Desimone CP, Seamon LG, Miller RA,
Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR Jr, Zhang
Z. Effectiveness of a multivariate index assay in the preoperative assessment
of ovarian tumors. Obstet Gynecol. 2011 Jun;117(6):1289-97. 9. Yovino S, Grossman SA. Treatment of glioblastoma
in "elderly" patients. Curr Treat Options Oncol. 2011 Jun
8. [Epub ahead of print] 10. Yu G, Zhang B, Bova GS, Xu J, Shih IM, Wang
Y. BACOM: in silico detection of genomic deletion types and correction
of normal cell contamination in copy number data. Bioinformatics. 2011
Jun 1;27(11):1473-1480. Epub 2011 Apr 15. 1. Antonarakis ES, Armstrong AJ. Evolving standards
in the treatment of docetaxel-refractory castration-resistant prostate
cancer. Prostate Cancer Prostatic Dis. 2011 May 17. [Epub ahead of print] 2. Bolaños-Meade J, Smith BD, Gore SD,
McDevitt MA, Luznik L, Fuchs EJ, Jones RJ. 5-azacytidine as salvage
treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
Biol Blood Marrow Transplant. 2011 May;17(5):754-8. Epub 2010 Oct 15. 3. Catalona WJ, Bailey-Wilson JE, Camp NJ, Chanock
SJ, Cooney KA, Easton DF, 4. Klein AP, Duggal P, Lee KE, Cheng CY, Klein
R, Bailey-Wilson JE, Klein BE. 5. Lin TL, Smith BD. Prognostically important
molecular markers in cytogenetically normal acute myeloid leukemia.
Am J Med Sci. 2011 May;341(5):404-8. 6. Parry EM, Alder JK, Lee SS, Phillips JA 3rd,
Loyd JE, Duggal P, Armanios M. Decreased dyskerin levels as a mechanism
of telomere shortening in X-linked dyskeratosis congenita. J Med Genet.
2011 May;48(5):327-33. Epub 2011 Mar 17. 7. Raabe EH, Keefer JR, Mitchell SE, Hong K, Difazio
M, Strouse JJ. Subtotal splenic embolization is a safe and effective
treatment for isolated splenic vascular tumors associated with consumptive
coagulopathy. J Pediatr Hematol Oncol. 2011 May 20. [Epub ahead of print] 8. Rajeshkumar NV, De Oliveira E, Ottenhof N,
Watters J, Brooks D, Demuth T, 9. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic
agents in patients 10. Rudek MA, New P, Mikkelsen T, Phuphanich S,
Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and
pharmacokinetic study of COL-3 in patients with recurrent high-grade
gliomas. J Neurooncol. 2011 May 6. [Epub ahead of print] 11. Ulahannan SV, Brahmer JR. Antiangiogenic agents
in combination with 1. Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey
RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children
with newly diagnosed diffuse intrinsic pontine gliomas: a report from
the Children's Oncology Group. Neuro Oncol. 2011 Apr;13(4):410-6. Epub
2011 Feb 22. 2. Jelovac D, Armstrong DK. Recent progress in
the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011
May-Jun;61(3):183-203. Epub 2011 Apr 26. 3. Li R, Hayward SD. The Ying-Yang of the virus-host
interaction: control of the DNA damage response. Future Microbiol. 2011
Apr;6:379-83. 4. Lipson EJ. Art in oncology: how patients add
life to their days. J Clin Oncol. 2011 Apr 1;29(10):1392-3. Epub 2011
Feb 7. 5. Paz-Priel I, Houng S, Dooher J, Friedman AD.
C/EBP{alpha} and C/EBP{alpha} oncoproteins regulate nfkb1 1. Dabrazhynetskaya
A, Ma J, Guerreiro-Cacais AO, Arany Z, Rudd E, Henter JI, Karre K, Levitskaya
J, Levitsky V. Syntaxin 11 marks a distinct intracellular compartment
recruited to the immunological synapse of NK cells to co-localize with
cytotoxic granules. J Cell Mol Med. 2011 Feb 22. doi: 10.1111/j.1582-4934.2011.01280.x.
[Epub ahead of print] 2. Dezern AE, Petri M, Drachman DB, Kerr D, Hammond
ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky
RA. High-dose cyclophosphamide without stem cell rescue in 207 patients
with aplastic anemia and other autoimmune diseases. Medicine (Baltimore).
2011 Mar;90(2):89-98. 3. Kasamon YL, Jones RJ, Gocke CD, Blackford AL,
Seifter EJ, Davis-Sproul JM, Gore SD, Ambinder RF. Extended follow-up
of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide
(4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol
Blood Marrow Transplant. 2011Mar;17(3):365-73. Epub 2010 Jul 22. 4. Paz-Priel I, Houng S, Dooher J, Friedman
AD. C/EBPα and C/EBPα oncoproteins regulate nfkb1
and displace histone deacetylases from NF-{kappa}B p50 homodimers to
induce NF-{kappa}B target genes. Blood. 2011 Feb 23. [Epub ahead of
print] 1. Brahmer JR, Dahlberg
SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences
in outcome with bevacizumab therapy: analysis of patients with advanced-stage
non-small cell lung cancer treated with or without bevacizumab in combination
with paclitaxel and carboplatin in the Eastern Cooperative Oncology
Group Trial 4599. J Thorac Oncol. 2011 Jan;6(1):103-8. 2. Henson BW, Johnson N, Bera A, Okoye ME, Desai
KV, Desai PJ. Expression of the HSV-1 capsid protein VP19C in Escherichia
coli: A single amino acid change overcomes an expression block of the
full-length polypeptide. Protein Expr Purif. 2010 Dec 28[Epub ahead
of print]. 3. Gandhi L, Camidge DR, Ribeiro de Oliveira M,
Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E,
Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H,
Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of
navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with
small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Jan
31 [Epub ahead of print]. 4. Guo H, Friedman AD. Phosphorylation of RUNX1
by cyclin-dependent kinase reduces direct interaction with HDAC1 and
HDAC3. J Biol Chem. 2011 Jan 7;286(1):208-15. 5. Kasamon YL. Prognostication and risk-adapted
therapy of Hodgkin's lymphoma using positron emission tomography. Adv
Hematol. 2011;2011:271595. 6. Levis M, Ravandi F, Wang ES, Baer MR, Perl
A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni
G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee
K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf
S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small
D, Smith BD. Results from a randomized trial of salvage chemotherapy
followed by lestaurtinib for patients with FLT3 mutant AML in first
relapse. Blood. 2011 Jan 26 [Epub ahead of print]. 7. Li L, Zhang L, Fan J, Greenberg K, Desiderio
S, Rassool FV, Small D. Defective non-homologous end joining blocks
B-cell development in FLT3/ITD mice. Blood. 2011 Jan 12[Epub ahead of
print]. 8. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B,
Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners
B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA,
Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage
colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma:
a phase II trial of safety, efficacy, and immune activation. Ann Surg.
2011 Jan 6 [Epub ahead of print]. 9. Ochs MF, Karchin R, Ressom H, Gentleman R.
Identification of aberrant pathway and network activity from high-throughput
data - Workshop Introduction. Pac Symp Biocomput. 2011:364-8. 10. Paz-Priel I, Cooke DW, Chen AR. Cyclophosphamide
for rapid-onset obesity, hypothalamic dysfunction, hypoventilation,
and autonomic dysregulation syndrome. J Pediatr. 2011 Feb;158(2):337-9.
11. Rudin CM, Mauer A, Smakal M, Juergens R, Spelda
S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan
R, Dowell B, Krivoshik A, Gordon G. Phase I/II study of pemetrexed with
or without ABT-751 in advanced or metastatic non-small-cell lung cancer.
J Clin Oncol. 2011 Feb 7 [Epub ahead of print]. 12. Scharpf RB, Ruczinski I, Carvalho B, Doan
B, Chakravarti A, Irizarry RA. A multilevel model to address batch effects
in copy number estimation using SNP arrays. Biostatistics. 2011 Jan;12(1):33-50.
Epub 2010 Jul 12. 13. van Engeland M, Derks S, Smits KM, Meijer
GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J
Clin Oncol. 2011 Jan 10 [Epub ahead of print]. 14. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke
J, Glockner S, Calmon M, Hooker C, Funes JM, Boshoff C, Smits KM, van
Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel
KE, Baylin SB, Ahuja N. Genomic and epigenomic integration identifies
a prognostic signature in colon cancer. Clin Cancer Res. 2011 Jan 28
[Epub ahead of print]. 1. Kanarek NF, Tsai
HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM. Geographic
proximity and racial disparities in cancer clinical trial participation.
J Natl Compr Canc Netw. 2010 Dec;8(12):1343-51. 2. Levis MJ. Will newer tyrosine kinase inhibitors
have an impact in AML? Best Pract Res Clin Haematol. 2010 Dec;23(4):489-94.
Epub 2010 Nov 5. 3. Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan
H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman
JM. Adjuvant chemoradiation therapy for adenocarcinoma of the distal
pancreas. Ann Surg Oncol. 2010 Dec;17(12):3112-9. Epub 2010 Aug 3. 4. Shamay M, Greenway M, Liao G, Ambinder RF,
Hayward SD. De novo DNA methyltransferase DNMT3b interacts with NEDD8-modified
proteins. J Biol Chem. 2010 Nov 19;285(47):36377-86. Epub 2010 Sep 16.
5. Villarroel MC, Rajesh Kumar NV, Garrido-Laguna
I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein
AP, Laheru D, Donehower RC, Hidalgo M. Personalizing cancer treatment
in the age of global genomic analyses: PALB2 gene mutations and the
response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther.
2010 Dec 6. [Epub ahead of print] 1. Bolaños-Meade
J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ. 5-azacytidine
as salvage treatment in relapsed myeloid tumors after allogeneic bone
marrow transplantation. Biol Blood Marrow Transplant. 2010 Oct 14. [Epub
ahead of print] 2. Edwards JP, Emens LA. The multikinase inhibitor
Sorafenib reverses the suppression of IL-12 and enhancement of IL-10
by PGE? in murine macrophages. Int Immunopharmacol. 2010 Oct;10(10):1220-8.
3. Fertig EJ, Ding J, Favorov AV, Parmigiani G,
Ochs MF. CoGAPS: an R/C++ package to identify patterns and biological
process activity in transcriptomic data. Bioinformatics. 2010 Nov 1;26(21):2792-3.
4. Hales RK, Banchereau J, Ribas A, Tarhini AA,
Weber JS, Fox BA, Drake CG. Assessing oncologic benefit in clinical
trials of immunotherapy agents. Ann Oncol. 2010 Oct;21(10):1944-51.
5. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide
for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov;17(6):493-9.
6. Peacock CD, Rudin CM. Skin deep and deeper:
multiple pathways in basal cell carcinogenesis. Cancer Prev Res (Phila).
2010 Oct;3(10):1213-6. 7. Ruble K, Hayat MJ, Stewart KJ, Chen AR. Bone
mineral density after bone marrow 1. Albesiano E, Davis
M, See AP, Han JE, Lim M, Pardoll DM, Kim Y. Immunologic consequences
of signal transducers and activators of transcription 3 activation in
human squamous cell carcinoma. Cancer Res. 2010 Aug 15;70(16):6467-76.
2. Brennan SK, Wang Q, Tressler R, Harley C, Go
N, Bassett E, Huff CA, Jones RJ, Matsui W. Telomerase inhibition targets
clonogenic multiple myeloma cells through telomere length-dependent
and independent mechanisms. PLoS One. 2010 Sep 1;5(9). pii: e12487.
4. Edwards JP, Emens LA. The multikinase inhibitor
Sorafenib reverses the suppression of IL-12 and enhancement of IL-10
by PGE? in murine macrophages. Int Immunopharmacol. 2010 Oct;10(10):1220-8.
5. Fertig EJ, Ding J, Favorov AV, Parmigiani G,
Ochs MF. CoGAPS: an R/C++ package to identify patterns and biological
process activity in transcriptomic data. Bioinformatics. 2010 Nov 1;26(21):2792-3.
6. Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner
A, Armstrong TD, Jaffee EM. CD8(+)Foxp3(+) tumor infiltrating lymphocytes
accumulate in the context of an effective anti-tumor response. Int J
Cancer. 2010 Sep 20. [Epub ahead of print] 7. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S,
Srinivasan S, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL.
Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric
acid with stem cell support for patients with high-risk osteosarcoma.
Cancer. 2010 Aug 16. [Epub ahead of print] 8. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide
for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov;17(6):493-9. 9. Marur S, D'Souza G, Westra WH, Forastiere AA.
HPV-associated head and neck cancer: a virus-related cancer epidemic.
Lancet Oncol. 2010 Aug;11(8):781-9. 10. Peacock CD, Rudin CM. Skin deep and deeper:
multiple pathways in basal cell carcinogenesis. Cancer Prev Res (Phila).
2010 Oct;3(10):1213-6. 11. Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD,
McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ, Rudek
MA, Smith BD. A pharmacodynamic study of sorafenib in patients with
relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-44.
Return to top of Publications - Oncology Archives
|
 |
|
||||||
|
|
|
|
|
JHM Appointments | Employment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM |
|
|
